Drug Discovery– tag –

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs...

In recent years, the question of whether RNA can serve as a viable therapeutic target has become one of the most exciting debates in life sciences and drug discovery. In recent years, the question of whether RNA can serve as a viable the...

Recent research highlights that aging and obesity each independently promote cancer progression and can act synergistically to worsen outcomes. Recent research highlights that aging and obesity each independently promote cancer progressi...

On August 19, 2025, U.S.-based biotech company Viking Therapeutics announced results from its Phase 2 trial of the oral obesity drug VK2735. While the therapy demonstrated up to 12.2% weight loss over 13 weeks, a high discontinuation rat...

This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modaliti...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, This article is the comprehensive summary of our Morningglorysciences Summer Beginner ...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Dru...

This article is a comprehensive summary of our Morningglorysciences Summer Beginner Series on anti-obesity drugs. This article is a comprehensive summary of our Morningglorysciences Summer Beginner Series on anti-obesity drugs. Throughou...

Introduction As of August 2025, the obesity drug race is undergoing major shifts. Eli Lilly and Novo Nordisk remain dominant, but biotech challengers and Big Pharma entries are redrawing the competitive map. This article reviews the late...

Even with solved structures, folding thermodynamics (ΔG) has long been hard to see. Even with solved structures, folding thermodynamics (ΔG) has long been hard to see. Recent work closes this gap with mega-scale measurements and a simple...

In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. In this final deep-dive of our beginner-friendly bispecific antibody series, we e...

In July 2025, the FDA began publishing past Complete Response Letters (CRLs). In July 2025, the FDA began publishing past Complete Response Letters (CRLs). Triangulating those releases with company disclosures and primary reporting shows...

In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. In this final volume, we summarize th...

Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significa...

On August 8, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for adults with unresectable or metastatic non-squamo...

On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals), a protease activator, for adult and pediatric patients (≥1 year) with progressive H3 K27M-mutant...

In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we delve into the crucial question: “Which targets should be selec In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we...